No Data
No money again! Shenzhen Chipscreen Biosciences has "burned" 0.9 billion in R&D expenses over three years and plans to raise another 0.96 billion, nearly 30% of which will be used to supplement cash flow.
shenzhen chipscreen biosciences announced a plan for private placement, planning to raise 0.96 billion yuan, with 0.71 billion yuan for innovative drug research and development, and 0.25 billion yuan for supplementary working capital, reaching a replenishment ratio of 26.04%; Multiple research pipelines continue to burn money for shenzhen chipscreen biosciences, with a total research and development expense of 0.927 billion yuan from 2021 to 2023, currently 17 indication pipelines are in clinical trial stage.
Shenzhen Chipscreen Biosciences Seeks 960 Million Yuan From Share Issuance
Star Evening News | kbc corporation,ltd. affiliated companies' silicon-based anode series products have formed bulk supply. shenzhen chipscreen biosciences plans to raise no more than 0.96 billion yuan through a private placement.
1. Polymax Materials' shareholder plans to reduce its shareholding by no more than 3% of the company's shares; 2. Micronano intends to repurchase shares ranging from 40 million yuan to 80 million yuan; 3. Beijing Hotgen Biotech Co.,Ltd. plans to repurchase shares at a range of 58 million yuan to -0.1 billion yuan; 4. Suzhou Hyc Technology plans to repurchase shares at a range of 25 million yuan to -50 million yuan.
Retail Investors Among Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 3.8% Last Week
Express News | The Phase III Clinical Trial Application for First-Line Treatment of Extensive Disease Small Cell Lung Cancer With Chiauranib Has Been Approved
Shenzhen Chipscreen Biosciences (688321.SH): Xilonium Capsule first-line treatment for extensive-stage small cell lung cancer has obtained a drug clinical trial approval letter.
Gelonghui November 1st, Shenzhen Chipscreen Biosciences (688321.SH) announced that the company and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for domestic production pharmaceutical registration clinical trials, approving the company's Sioronib capsules in combination with PD-(L)1 monoclonal antibodies and chemotherapy for first-line treatment in patients with extensive-stage small cell lung cancer. As of the date of this announcement, Sioronib has completed Phase III clinical trials for monotherapy in small cell lung cancer in China (for third-line and beyond treatment), and Sioronib in combination with chemotherapy for ovarian cancer.
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 30% Share Price Surge Not Quite Adding UpNo Data
No Data
